Penwest to develop version of Otsuka drug
DANBURY, Conn. Penwest Pharmaceuticals announced last week that it had signed a second agreement with Japan’s Otsuka Pharmaceutical to develop a version of an undisclosed Otsuka drug using Penwest’s TIMERx drug-delivery technology.
The deal, announced Tuesday, is the second between Otsuka and Danbury, Conn.-based Penwest. The two companies began collaborating in September 2007 to develop drugs using TIMERx, a controlled-release delivery system.
“We are pleased to have signed this second research and development agreement with Otsuka,” Penwest president and chief executive officer Jennifer Good said in a statement. “These collaborations around our proprietary drug delivery technologies are important for us both financially and scientifically.”
NOCA recognizes PTCB’s Corrigan with Certification Industry Leadership Award
WASHINGTON Melissa Murer Corrigan, executive director and chief executive officer of the Pharmacy Technician Certification Board, has received the 2008 Certification Industry Leadership Award from the National Organization for Competency Assurance, PTCB announced Tuesday.
PTCB said the award recognized Murer Corrigan’s leadership in the field of certification and licensure. She has certified more than 320,000 pharmacy technicians as the founding executive of PTCB.
“This award is a tribute to the hard work and dedication of all my colleagues and partners involved in making PTCB a success since our founding in 1995,” Murer Corrigan said in a statement. “The certification of pharmacy technicians in the U.S. has advanced the patient safety of millions of Americans, and I am so proud of the PTCB team and all of our certified technicians.”
FDA warns Shionogi to end unsupported Cedax claims
ROCKVILLE, Md. The Food and Drug Administration released a warning letter to Shionogi and Co. Tuesday regarding its antibiotic Cedax.
The FDA said the company made inflated claims about Cedax (ceftibuten) and downplayed the health risks associated with it. Promotional materials sent to doctors claimed the drug had “excellent tolerability,” even though data did not support the claim.
The drug is approved for treating mild to moderate bacterial infections.